Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling - Karanika, Styliani; Karantanos, Theodoros; Li, Likun; Wang, Jianxiang; Park, Sanghee; Yang, Guang; Zuo, Xuemei; Song, Jian H.; Maity, Sankar N.; Manyam, Ganiraju C.; Broom, Bradley; Aparicio, Ana M.; et al. (Cell reports (Cambridge), 2017)
Keywords: androgen receptor; Androgen Receptor Antagonists - pharmacology; Animals; Apoptosis - drug effects; Ataxia Telangiectasia Mutated Proteins - metabolism; ATR; AZD7762; Biomarkers - metabolism; CDC6; Cell Cycle Checkpoints - drug effects; Cell Cycle Proteins - metabolism; Cell Line, Tumor; Checkpoint Kinase 1 - metabolism; Chk1; DNA damage; DNA Damage - drug effects; DNA Damage - physiology; DNA Replication - drug effects; DNA-Binding Proteins - metabolism; enzalutamide; Humans; Male; Mice; Mice, Nude; Nuclear Proteins - metabolism; Phosphorylation - drug effects; prostate cancer; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - metabolism; Receptors, Androgen - metabolism; Signal Transduction - drug effects; Thiophenes - pharmacology; TOPBP1; Urea - analogs & derivatives; Urea - pharmacology; prostate cancer; androgen receptor; DNA damage; AZD7762; CDC6; Chk1; TOPBP1; enzalutamide; ATR